Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections

BACKGROUND: Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer. A hallmark of chronic hepatitis B is a dysfunctional HBV-specific T-cell response. We therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Maravelia, Panagiota, Frelin, Lars, Ni, Yi, Caro Pérez, Noelia, Ahlén, Gustaf, Jagya, Neetu, Verch, Georg, Verhoye, Lieven, Pater, Lena, Johansson, Magnus, Pasetto, Anna, Meuleman, Philip, Urban, Stephan, Sällberg, Matti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781452/
https://www.ncbi.nlm.nih.gov/pubmed/31994701
http://dx.doi.org/10.1093/infdis/jiaa036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781452/
https://www.ncbi.nlm.nih.gov/pubmed/31994701
http://dx.doi.org/10.1093/infdis/jiaa036

Ejemplares similares